Clinical Pharmacist Impact Study

NCT07269002 | Completed

• 1 other identifier: F PH-BSU-HREC-0001025
• Study Type: interventional
• Target: 3,600
• Locations: 1 country
• Sites: 1

Brief Summary

This study evaluated a pharmacist-led medication-safety program in hospitalized patients. The program included routine inpatient medication review and the use of smartphone-based clinical decision-support applications to identify potential medication issues and support therapeutic decision-making. The study was conducted in both adult and pediatric inpatients as part of routine clinical care. No investigational drugs or devices were used.

Conditions

Medication Safety; Preventable Medication Harm; Pharmacotherapy Optimization

Keywords

Clinical pharmacist; Medication review; Smartphone clinical apps

Outcome Measures

Primary Outcomes (2)

• Medication-Safety Composite Indicator

  From hospital admission through study completion (an average of 5 days)

• Medication-Safety Composite Indicator

  A composite measure assessing medication-safety performance in inpatient settings, including identification of medication discrepancies, potential medication risks, and pharmacist-detected issues during routine clinical care. The measure reflects overall improvement in medication-safety processes following the implementation of the pharmacist-led program.

  From hospital admission through study completion (an average of 5 days)

Study Arms (2)

Control

NO INTERVENTION

Usual inpatient medication practices before implementation of the pharmacist-led safety program.

Intervention

OTHER

Structured pharmacist-led medication review and safety support using smartphone clinical decision-support applications.

Other: Pharmacist-Led Medication Safety Program

Interventions

Pharmacist-Led Medication Safety Program OTHER

A structured clinical pharmacist program that includes inpatient medication review, identification of potential medication-related problems, and use of smartphone-based clinical decision-support applications to support therapeutic decision-making and enhance medication safety practices.

Intervention

Eligibility Criteria

• Age: 2 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Hospitalized patients receiving medication therapy
• Adult and pediatric inpatients
• Patients receiving at least one scheduled medication dose during admission

You may not qualify if:

• Patients not receiving any pharmacologic treatment
• Patients admitted for procedures with no medication administration
• Patients discharged before assessment could be performed

Sponsors & Collaborators

• Beni-Suef University: lead

Study Sites (1)

Clinical Research Coordination Unit

Banī Suwayf, Egypt

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Pharmacist and Principal Investigator

Study Record Dates

• First Submitted: November 21, 2025
• First Posted: December 8, 2025
• Study Start: March 15, 2025
• Primary Completion: September 15, 2025
• Study Completion: September 15, 2025
• Last Updated: December 8, 2025

Record last verified: 2025-12

Locations

EG (1)